Earth Science Tech, Inc. Initiates Pre-Launch on its MSN-2 Human Clinical Trials with Clinique Sante Amite


Doral, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company that operates in the fields of industrial hemp cannabinoid (CBD), nutraceutical, pharmaceutical, medical device, research and development, initiates the pre-launch of its MSN-2 human clinical trials with Clinique Sante Amite.

The previously announced pre-launch clinical study, (https://www.globenewswire.com/news-release/2017/10/10/1143709/0/en/Earth-Science-Tech-Inc-Partners-with-Centre-SIDA-Amite-Clinic-to-Commence-Final-Pre-Launch-MSN-2-Human-Research-Study.html), has been initiated. Patient enrollment has already begun, and the reactions to the study and the product have been very positive thus far. The general approval and acceptance of the product’s self-sampling basis has led to the nurses having no difficulty enrolling participants.

The patients have enthusiastically agreed to help the company develop this new, alternative technology for the detection and follow-up of various sexually transmitted infections (STI), starting with Chlamydia and Gonorrhea.

Last week, Dr. Michel Aubé, ETST CEO and Chief Scientific Officer, held a preceptorship with Dr. Jean Robert, a physician at Clinique Santé Amitié. Dr. Aubé spent a full afternoon with Dr. Robert and his patients, sitting in on their private consultations. The goal of this rapprochement is to demonstrate the reality of AIDS and HIV to health workers and other people and institutions interested in helping fight this deadly pandemic.

“This exercise reinforces our desire to prevent the transmission of avoidable infections and to help people living with incurable illnesses,” said Dr. Aubé, obviously moved by his afternoon with Dr. Robert. “You cannot imagine the reality for people living with HIV if you are not close to them. My experience with Dr. Robert and his patients was amazing. Personally, I believe that each and every patient should be treated the way Dr. Robert takes care of his patients. Without his help, many of them would likely be dead today. He has such a long track record as an expert in community health, and as a compassionate teacher. What makes him so special is how he listens to his patients. He told me that he has learned a great deal from them.” 

Clinique Santé Amitié is a community health center that offers free consultation with a physician and useful services like: Workshops on health, STIs and HIV/AIDS in particular with kiosk for participation in public events. Practitioners are available to visit schools, organizations, institutions, or any other interested entities. They have program for free distribution of condoms, distribution of injection equipment, distribution of printed educational material, support for sex workers, support for homosexual, bisexual, and transgender people, as well as those questioning their gender identity, support for people living with HIV-AIDS, and their loved ones.

ETST will support the clinic as much as possible and participate in their prevention efforts by offering the MSN-2 self-screening test very soon to woman in different countries. The company has completed a significant part of the branding exercise with Absolu Communication and the commercial name of the new medical device will be finalized in next weeks.

African markets
In support of ETST’s initiative to open the African market for its hemp oil and medical device products (Nanoderm and MSN-2) the company will have a dedicated kiosk at the Djibouti International Trade Fair December 3-7. http://www.foiredjibouti.com/index.php/en/?start=2

The kiosk will be staffed by a physician and a businessman who are both native to Djibouti, and who will work to develop relationships with important trade administrators and stakeholders in the East African nation.

Resting on the Gulf of Aden at the entry to the Red Sea, Djibouti is a gateway to many other African countries totalizing more than 400 million people, as well as the Middle East. ETST will work closely with health authorities there to introduce other medical devices that will meet local needs in as short a period of time as possible.

About Earth Science Tech, Inc. (ETST): Earth Science Tech has the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the world's best supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research performed alongside the University of Central Oklahoma and DV Biologics laboratory, prove we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil. 

To learn more and to buy CBD Hemp Oil please visit: www.earthsciencetech.com

View ETST's accomplishments and reports on its High-Grade CBD Hemp Oil: (here)

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.

To learn more please visit: www.Earthsciencepharmaceutical.com

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide.

To learn more please visit: www.Cannabisthera.com

About KannaBidioiD: KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioid, Inc. is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by it's unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.

To learn more please visit: www.kannabidioidinc.com

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.



            

Kontaktdaten